New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 4, 2012
05:55 EDTNVS, NVS, PFE, PFE, JNJ, JNJ, RHHBY, RHHBY, VOD, VOD, WBMD, WBMD, DB, DB, SNY, SNY, AZN, AZN, MRK, MRK, GSK, GSK, AGEN, AGENFinancial Times to hold a conference
Global Pharmaceutical & Biotechnology Conference 2012 is being held in London on December 4-5.
News For NVS;GSK;MRK;AZN;SNY;DB;WBMD;VOD;RHHBY;JNJ;PFE;AGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
April 9, 2015
08:04 EDTPFEPfizer launches PCSK9 competitive grants program
Subscribe for More Information
April 8, 2015
16:22 EDTNVSOn The Fly: Closing Wrap
Subscribe for More Information
15:19 EDTRHHBYRoche says receives European approval for Avastin plus chemotherapy
Roche announced that the European Commission approved Avastin -- bevacizumab -- in combination with standard chemotherapy for the treatment of adult patients with persistent, recurrent or metastatic carcinoma of the cervix. The EU approval was based on the significant survival benefit in the pivotal GOG-0240 study, which showed that women who received Avastin plus chemotherapy had a statistically significant 26% reduction in the risk of death, representing a median improvement in survival of nearly four months, compared to women who received chemotherapy alone.
14:23 EDTNVSAdditional bidders for Perrigo could emerge after Mylan offer, says Stifel
Subscribe for More Information
13:08 EDTWBMDGoldman reverses WebMD downgrade back to Neutral from Sell
Goldman reversed this morning's downgrade of WebMD from Sell back to Neutral. Goldman's analyst said it erroneously included convertible notes in both its diluted share count and net debt calculation, which resulted in a an incorrect enterprise value calculation. The firm upgraded its rating back to Neutral and increased its price target to $57 from $40.
10:01 EDTWBMDOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Almost Family (AFAM) downgraded to Neutral from Outperform at Baird... Angie's List (ANGI) downgraded to Neutral from Buy at B. Riley... Annaly Capital (NLY) downgraded to Underperform from Market Perform at FBR Capital... Apple (AAPL) downgraded to Hold from Buy at Societe Generale... Calamos (CLMS) downgraded to Underperform from Market Perform at Keefe Bruyette... Catamaran (CTRX) downgraded to Hold from Buy at Argus... Cinemark (CNK) downgraded to Neutral from Buy at Janney Capital... Crestwood Equity (CEQP) downgraded at BofA/Merrill... Cummins (CMI) downgraded to Neutral from Buy at Goldman... Kinder Morgan (KMI) downgraded to Buy from Conviction Buy at Goldman... L'Oreal (LRLCY) downgraded to Neutral from Outperform at Exane BNP Paribas... NextEra Energy Partners (NEP) downgraded to Neutral from Buy at Goldman... Regal Entertainment (RGC) downgraded to Neutral from Buy at Janney Capital... Trina Solar (TSL) downgraded at BofA/Merrill... WebMD (WBMD) downgraded to Sell from Neutral at Goldman... Yingli Green Energy (YGE) downgraded at BofA/Merrill... Zep Inc. (ZEP) downgraded to Sell from Buy at Wunderlich.
09:23 EDTJNJJohnson & Johnson April volatility elevated into Q1 and outlook
Subscribe for More Information
09:20 EDTWBMDOn The Fly: Pre-market Movers
Subscribe for More Information
07:33 EDTMRKAdvaxis, Merck begin enrollment in Phase 1/2 of ADJX-PSA with Keytruda
Advaxis (ADXS) and Merck (MRK) announced that enrollment has initiated in the Phase 1/2 clinical trial evaluating the combination of ADXS-PSA, an investigational Lm-LLO immunotherapy, and Keytruda, the first anti-PD-1 therapy approved in the United States, in patients with previously treated, metastatic castration-resistant prostate cancer, or mCRPC. The clinical trial, KEYNOTE-046, is the first-in-human study of Advaxis's lead Lm-LLO immunotherapy candidate for prostate cancer. It is the second study initiated to evaluate the use of KEYTRUDA in the treatment of advanced prostate cancer. ADXS-PSA and KEYTRUDA are members of a class of cancer treatments known as immuno-oncology therapies. Data from preclinical studies suggest that Advaxis Lm-LLO immunotherapies in combination with a PD-1 antibody may lead to an enhanced anti-tumor immune response. The results from KEYNOTE-046 will determine the future clinical development program for the combination.
07:24 EDTJNJNeurotechnology Industry Organization to hold a conference
Subscribe for More Information
07:06 EDTAGENAgenus acquires Celexion assets for $1M in cash, $3M in stock
Subscribe for More Information
07:04 EDTMRKMerck's investigational Hep C therapy granted breakthrough therapy designations
Subscribe for More Information
06:12 EDTWBMDWebMD downgraded to Sell from Neutral at Goldman
Subscribe for More Information
06:06 EDTAZNInovio selected by DARPA to lead $45M Ebola prevention program
Subscribe for More Information
April 7, 2015
16:12 EDTAZNRegulus up 5% after RG-125 selected as clinical candidate by AstraZeneca
Subscribe for More Information
16:12 EDTAZNRegulus RG-125 selected as clinical candidate by AstraZeneca
Regulus Therapeutics (RGLS) announced the selection of RG-12, a GalNAc-conjugated anti-miR targeting microRNA-103/107, or miR-103/107, for the treatment of Non Alcoholic Steatohepatitis, or NASH, in patients with type 2 diabetes/pre-diabetes, as a clinical candidate by AstraZeneca (AZN) under the companies' strategic alliance to discover, develop and commercialize microRNA therapeutics. RG-125 is the first compound from the alliance to be selected for clinical development by AstraZeneca. In connection with the candidate selection, AstraZeneca will pay Regulus $2.5M and will assume development of the program following acceptance of an Investigational New Drug application. In the near term, Regulus and AstraZeneca plan to submit key preclinical data on the RG-125 program to be presented at a scientific meeting later this year and expect to initiate a Phase I study of RG-125 in humans by the end of 2015.
10:28 EDTVODMavenir announces VoLTE launch with Vodafone Germany
Mavenir Systems (MVNR) announced its VoLTE application solution was launched by Vodafone Germany (VOD), who announced during CEBIT 2015 the first commercially available VoLTE service in the European market. Mavenirís virtualized VoLTE application solution consists of its IMS Telephony Application Server, Application Gateway and Media Resource Function.
08:09 EDTPFEPfizer, Merck KGaA finalize agreement to co-promote XALKORI
Merck KGaA (MKGAY) and Pfizer (PFE) announced the finalization of the co-promotion agreement allowing the companies to co-promote Pfizerís anaplastic lymphoma kinase inhibitor XALKORI. Under the agreement, XALKORI will be co-promoted in two waves, the first of which will begin in the second and third quarters of 2015 in the United States, Canada, Japan and five European Union countries: France, Germany, Italy, Spain and the United Kingdom. In the U.S. and Canada, XALKORI will be co-promoted by EMD Serono, the U.S. and Canadian biopharmaceutical businesses of Merck KGaA. The second wave will begin in 2016 and includes China and Turkey. n 2015, Merck KGaA will receive a reimbursement associated with its promotion of XALKORI, followed by an 80% for Pfizer, 20% for Merck KGaA profit sharing on the product starting in 2016. The co-promotion term will last through December 31, 2020 for the U.S., Canada, Japan, France, Germany, Italy, Spain and the U.K. and from January 1, 2016 through December 31, 2021 in China and Turkey. Pfizer will report the sales of XALKORI in countries where it is co-promoted with Merck KGaA.
07:14 EDTNVS, AZN, GSK, RHHBY, MRK, PFE, SNYEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.
07:02 EDTPFEGlycoMimetics updates on Pfizer's plans to initiate Phase 3 Rivipansel trial
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use